Profectus BioSciences has received $6.25 million in National Institute of Allergy and Infectious Diseases grants, including $2.9 million in Small Business Innovative Research grants. The company's adjuvant profile focuses on harnessing the body's immune system to fight off viruses and cancers more effectively. Earlier this week, the company received an additional $4.4 million for its HIV vaccine. Profectus release